Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.

Wong BC, Ravani P, Manns BJ, Lewin A, Zhang X, Chin R, Hemmelgarn BR, Tonelli M, Oliver MJ, Quinn RR.

Am J Kidney Dis. 2013 Nov;62(5):947-52. doi: 10.1053/j.ajkd.2013.05.017.

PMID:
23856380
2.

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.

Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL.

Am J Kidney Dis. 2013 Jan;61(1):44-56. doi: 10.1053/j.ajkd.2012.07.014.

3.
4.

The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Ishigami J, Onishi T, Shikuma S, Akita W, Mori Y, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y.

Clin Exp Nephrol. 2013 Feb;17(1):106-14. doi: 10.1007/s10157-012-0659-6.

PMID:
22752396
5.

Erythropoietic response and outcomes in kidney disease and type 2 diabetes.

Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators..

N Engl J Med. 2010 Sep 16;363(12):1146-55. doi: 10.1056/NEJMoa1005109.

6.

Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.

Ogawa T, Shimizu H, Kyono A, Sato M, Yamashita T, Otsuka K, Nitta K.

Int Urol Nephrol. 2014 Jan;46(1):151-9. doi: 10.1007/s11255-013-0494-z.

PMID:
23807369
7.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
8.

RBC transfusions among hemodialysis patients (1999-2010): influence of hemoglobin concentrations below 10 g/dL.

Gilbertson DT, Monda KL, Bradbury BD, Collins AJ.

Am J Kidney Dis. 2013 Nov;62(5):919-28. doi: 10.1053/j.ajkd.2013.05.004.

PMID:
23815986
9.

Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.

Suttorp MM, Hoekstra T, Mittelman M, Ott I, Krediet RT, Dekker FW, Putter H.

Pharmacoepidemiol Drug Saf. 2015 Oct;24(10):1068-75. doi: 10.1002/pds.3855.

PMID:
26265483
10.

Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.

McCarthy JT, Hocum CL, Albright RC, Rogers J, Gallaher EJ, Steensma DP, Gudgell SF, Bergstralh EJ, Dillon JC, Hickson LJ, Williams AW, Dingli D.

Mayo Clin Proc. 2014 Jan;89(1):87-94. doi: 10.1016/j.mayocp.2013.10.022.

PMID:
24388026
11.

Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.

Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K.

J Am Soc Nephrol. 2006 Apr;17(4):1181-91.

12.

Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.

Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA, Good CB; ESA Clinic Study Group..

Am J Kidney Dis. 2012 Sep;60(3):371-9. doi: 10.1053/j.ajkd.2012.04.013.

PMID:
22633556
13.

A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.

Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM; HERO Study Collaborative Group..

Am J Kidney Dis. 2015 Jan;65(1):49-57. doi: 10.1053/j.ajkd.2014.06.020.

PMID:
25115616
14.
15.

Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.

Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, Brookhart MA, Goldstein BA.

Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339.

16.

Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study.

Portolés JM, de Francisco AL, Górriz JL, Martínez-Castelao A, López-Gómez JM, Arias M, de la Cruz JJ, Cases A, Fernández E, Aljama P.

Kidney Int Suppl. 2008 Dec;(111):S82-7. doi: 10.1038/ki.2008.524.

PMID:
19034334
17.

Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.

Sibbel SP, Koro CE, Brunelli SM, Cobitz AR.

BMC Nephrol. 2015 Aug 18;16:144. doi: 10.1186/s12882-015-0138-x.

18.

Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.

Foley RN, Curtis BM, Parfrey PS.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1669-75. doi: 10.2215/CJN.02100508.

19.

Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.

Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y, Fukuhara S.

Am J Kidney Dis. 2012 Jan;59(1):108-16. doi: 10.1053/j.ajkd.2011.07.014.

PMID:
21890255
20.

Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.

Choi P, Farouk M, Manamley N, Addison J.

Adv Ther. 2013 Nov;30(11):1007-17. doi: 10.1007/s12325-013-0063-y.

Items per page

Supplemental Content

Support Center